SEC Company Response from KAZIA THERAPEUTICS (KZIA) — Dec 22, 2025
KAZIA THERAPEUTICS LTD
Date: Dec. 22, 2025 · CIK: 0001075880 · Accession: 0001193125-25-328702
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290598
Letter
December 22, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kazia Therapeutics Limited Acceleration Request for Registration Statement on Form F-1 File No. 333-290598 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Kazia Therapeutics Limited (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “ Registration Statement ”) be accelerated to December 23, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Will Wang of Goodwin Procter LLP at (212) 459-7083.
Sincerely,
KAZIA THERAPEUTICS LIMITED
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 22, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kazia Therapeutics Limited Acceleration Request for Registration Statement on Form F-1 File No. 333-290598 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Kazia Therapeutics Limited (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “ Registration Statement ”) be accelerated to December 23, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Will Wang of Goodwin Procter LLP at (212) 459-7083. Sincerely, KAZIA THERAPEUTICS LIMITED /s/ John Friend John Friend Chief Executive Officer cc: John Friend, Chief Executive Officer, Kazia Therapeutics Limited Stephanie Richards, Esq., Goodwin Procter LLP Will Wang, Esq., Goodwin Procter LLP